specialty (Urology), then by principal procedure CPT code 55842,. Cases were excluded if other procedure CPTs coded for cystectomy, urinary diversion using intestinal segments, or kidney/liver/bone resection. Categorical variables were analyzed using chi square test and continuous variables were analyzed using T-test.
INTRODUCTION AND OBJECTIVES: Nerve sparing (NS)
procedures have demonstrated improved potency preservation in radical prostatectomy (RP) . A better understanding of prostate neuroanatomy and advancement in surgical techniques has moved from the "all-or-none" concept to a graduated NS to get the best compromise between cancer control and functional outcome. However, the preoperative planning of a NS approach is mostly based on subjective pre or intraoperative variables. Our aim is to provide a user-friendly statistical tool, with a decision rule, to standardize decision making in grading the NS approach.
METHODS: A total of 11794 prostatic lobes, from a cohort of 6360 patients who underwent robot-assisted RP between January 2008 and January 2016 in a high-volume centre have been evaluated. The amount of extracapsular extension (ECE) maximum width of every prostatic lobe was calculated. Clinicopathological features were included in a statistical algorithm. Five multivariable models were estimated for: presence of ECE and ECE width greater than 1, 2, 3, and 4 mm. A fiveezone decision rule is proposed. Using a graphical interface surgeons can view pre-treatment characteristics and a curve showing the estimated probabilities for ECE amount and the areas identified by the decision rule.
RESULTS: Out of 6360 patients, 1803 (28.4%) were affected by non organ confined disease. Of 11794 prostatic lobes, ECE was present in 1351 lobes (11.4%) and was extended beyond the prostatic capsule for more than 1, 2, 3, 4 mm in 498 (4.2%), 261 (2.2%), 148 (1.3%), 99 (0.8%) cases, respectively. The width of ECE was up to 15 mm (IR 1.00 -2.00). The 5 logistic models showed good predictive performance; the area under the ROC curve was: 0.81 for ECE, and 0.84, 0.85, 0.88, and 0.90 for ECE width greater than 1, 2, 3, and 4 mm, respectively. The proposed graphical tool provides valuable support to the surgeon in the choice of the side-specific surgical strategy and in the counseling with the patient. CONCLUSIONS: Our predictive tool based on 7 variables can accurately predict the presence and the amount of ECE in prostate cancer. Furthermore, a graphical interface supports surgeons in patient counselling and in the choice of the side-specific surgical strategy (Fig.1) INTRODUCTION AND OBJECTIVES: Hyaluronidase (HAase) family of enzymes degrades hyaluronic acid (HA). In the human genome there are 6 HAase gens clustered on chromosomes 3p21.3 (HYAL-1, -2, -3) and 7q31.3 (HYAL-4, PH20, HYALP1). HYAL-4 is suspected to be a chondroitinase (Chase), i.e. a chondroitin sulfatedegrading enzyme. To date no study has linked HYAL-4 to any disease or biological activity.
METHODS: Q-PCR was performed for measuring the mRNA levels of 6 HAase genes in BCa cell lines, 59 bladder tissues (normal (NBL) ¼ 22; tumor (TBL) ¼ 37) and 160 urine specimens (BCa ¼ 52; normal ¼ 18; history of BCa ¼ 30; benign conditions ¼ 59). A subset of urine specimens was used to measure chase activity using a novel ELISA. By stable transfection of normal urothelial and BCa cells, HYAL-4 function was analyzed in vitro (proliferation, motility, invasion, e636 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 immunoblotting, Q-PCR assays) and in vivo (s.c. and orthotopic xenograft models). RESULTS: HYAL1, HYAL4 and HYALP1 mRNA levels were significantly (6-13-fold) elevated in TBL tissues when compared to NBL tissues (P<0.001). In multivariate analysis, in addition to HYAL-1, HYAL-4 was an independent prognosticator of metastasis and death due to BCa (P<0.001). HYAL1, HYAL4 and HYALP1 mRNA levels were also significantly elevated in BCa patients 0 urine (P< 0.0001). Chase activity was significantly elevated in BCa patients, as compared to BGU or HXBCa patients (P<0.0001; 100% sensitivity and 84% specificity to detect BCa). Overexpression of HYAL-4 in normal urothelial and BCa cells significantly increased invasion and chemotactic motility (> 3-fold) and enriched a cancer stem cell phenotype-spheroid formation, increased ALDH1 expression and activity, and a cytokeratin 4, 14, 17 molecular signature. HYAL-4 expression up-regulated CD44, MMP-9 and Akt signaling. In s.c. and orthotopic BCa models, HYAL-4 expression increased both tumor growth and metastasis of BCa cells and tumor growth in normal urothelial cells.
CONCLUSIONS: This is the first study that links HYAL4 to cancer biology and demonstrates it to be a molecular determinant of BCa. The melanoma-associated antigen-A (MAGE-A) family is a highly attractive target for cancer immunotherapy because of its broad representation in cancer tissues but restricted expression in normal tissues. Recent studies have shown significant expression of MAGE A antigen in urothelial carcinoma (UC). We aim to assess MAGE A and Programmed Death-Ligand 1 (PD-L1) expression in a large UC cohort spanning multiple grades, stages, and including metastatic disease to inform immunotherapeutic approaches to the treatment of UC.
METHODS: Analysis of MAGE A and PD-L1 expression on neoplastic cells using immunohistochemical staining of tissue microarrays from patients with bladder cancer (T1-4, Nx, M0-1) was done using the H-score system (a measure that simultaneously accounts for frequency and intensity of expression). We compared differential expression as well as H-scores between superficial vs. invasive, low (LG) vs. high grade (HG) as well as localized (LO) (T1-2) vs. locally advanced (LA) (T3-4) and metastatic vs non-metastatic. Comparisons between groups were done using Student's T-test for continuous variables and Chi-Square for categorical variables.
RESULTS: There were a total of 443 cases, of which 40% stained positively for MAGE A. Furthermore, 26% of the cohort was > 50% positive for MAGE expression. Expression was positive in 36% of the LG vs. 64% of HG patients (p¼<0.001). Expression of MAGE was 48% in LO vs. 52% in LA (p¼0.02). Sub-stratifying by individual stage, pT2 had the highest expression (28%) and pT4 had the lowest (2%). Mean H-score for MAGE A between HG vs. LG was 59 vs. 30, respectively (p¼<0.001), Tis (15) vs. T1-4 (45) was also significant (p¼<0.001). LO vs. LA was not significant (p¼0.8), similarly metastatic vs. non-metastatic (p¼0.59). Mean H-score for PD-L1 was significantly higher in LA vs LO (26% vs. 10% p¼0.02), and in HG vs. LG (21% vs. 2% p¼<0.001). No significant difference was noted between metastatic vs. non-metastatic (p¼0.71). There was no significant correlation between MAGE and PD-L1 expression for HG (p¼0.08) or LA (p¼0.12).
CONCLUSIONS: This is the largest report of the expression of MAGE A antigen in urothelial carcinoma showing a significant expression in higher grade and stage urothelial carcinoma as well as significant proportion of patients with >50% positive expression. In conjunction with high PD-L1 expression in HG and LA these data support MAGE targeted immune interventions, including adoptive therapy with TCR engineered T cells for UC with or without combination with checkpoint inhibitor. METHODS: We identified 44 cases of MPUC that had tissue available for FISH and IHC at our institute, of which an NOS component sufficient for both FISH and IHC was identified in 37 cases. We followed the updated ASCO/CAP Guidelines for breast cancer and as such amplification was defined by a HER2/CEP17 ratio of 2.0 or > 6 copies of the gene and HER2 overexpression was considered with IHC scores of 2þ and 3þ.
RESULTS: In urothelial tumors with both MP and NOS components (n ¼ 37), ERBB2 amplification in MP and NOS components was present in 25 and 16 cases respectively. ERBB2 amplification was significantly higher in the MP component compared to NOS component within the same tumor (67.57% vs. 43.24%, p ¼ 0.049). HER2 overexpression in MP and NOS components was present in 25 and 13 cases respectively. HER2 overexpression was significantly higher in the MP component compared to NOS component within the same tumor (67.56% vs. 35.13%, p ¼ 0.012). In addition, ERBB2 amplification strongly correlated with HER2 overexpression in both MP (rho ¼ 0.65, p<0.001) and NOS (rho ¼ 0.74, p<0.001) components. In this cohort (n ¼ 44), tumor stage and lymph node status were significant predictors for overall survival (p ¼ 0.01, <0.001 respectively). However, ERBB2 amplification and HER2 overexpression in MP component were not associated with patients 0 survival outcome (p¼1.00, 0.75 respectively).
CONCLUSIONS: The majority of MPUC is associated with ERBB2 amplification and HER2 overexpression. In MPUC, ERBB2 amplification and HER2 overexpression were preferentially but not exclusively identified in MP component compared to NOS component. Our findings provide evidence for intratumoral heterogeneity of ERBB2 amplification and HER2 expression in MPUC. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e637
